Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003086006 | SCV003473177 | uncertain significance | Erythrocytosis, familial, 3 | 2022-02-28 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. This variant has not been reported in the literature in individuals affected with EGLN1-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces alanine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 114 of the EGLN1 protein (p.Ala114Thr). |
Ambry Genetics | RCV004071905 | SCV005028488 | uncertain significance | not specified | 2023-10-09 | criteria provided, single submitter | clinical testing | The p.A114T variant (also known as c.340G>A), located in coding exon 1 of the EGLN1 gene, results from a G to A substitution at nucleotide position 340. The alanine at codon 114 is replaced by threonine, an amino acid with similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |